Project Grant K99HL171887
Award Date
8/15/24
Completion Date
6/30/26
Dollars Obligated
$100K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $149,804 to The University of Texas Southwestern Medical Center to study the native in situ structure of myofibrils within intact human cardiomyocytes derived from induced pluripotent stem cells. The research aims to use advanced cryo-electron tomography techniques to directly observe conformational alterations in cardiac b-myosin due to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $694,754 to The Washington University in St. Louis to conduct research on understanding the molecular and cellular mechanisms underlying cardiomyopathies and identifying potential therapeutic interventions. The key objectives are to: 1) determine if patient mutations in the troponin gene can be grouped based on common molecular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research into the regulation of the autophagy pathway and its relationship to cardiomyopathy and heart failure. The $2,185,454 award to Tufts Medical Center Parent, Inc. will fund a 4-year study investigating the mechanistic basis of a genetic variant (FHOD3V1151I) associated with hypertrophic cardiomyopathy. Key objectives...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) provides $549,796 to Cedars-Sinai Medical Center to conduct research focused on understanding how mutations in the TET2 and IDH2 genes associated with acute myeloid leukemia (AML) can impact cardiac metabolism and lead to cardiomyopathy and heart failure. The key research objectives are to: 1) Examine alterations in heart oxidative metabolism in response to TET2 or...
This $704,071 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to elucidate the molecular mechanisms by which mutations in the LMNA gene promote cardiac conduction disorders. The project aims to establish the pathological function of LMNA in the development of cardiac conduction disorders, which can lead to conditions like sick sinus syndrome and atrioventricular block. A key...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,400 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan. The 5-year grant, which commenced on May 15, 2025, supports research by Dr. Joshua Meisner, a pediatric cardiologist and physician-scientist, to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy (HCM) caused by MYBPC3 gene mutations. The research aims to develop...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $116,250.00 to the Regents of the University of Minnesota to conduct research on identifying the underlying causes of cardiomyopathy. The research aims to evaluate the use of cardiac magnetic resonance imaging to reclassify the causes of cardiomyopathy, which could lead to more accurate diagnosis and appropriate...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $205,469 to The Regents of the University of California, San Francisco to conduct research on the role of the emerin protein in human atrial cardiomyocytes. The primary objectives are to understand emerin's function in regulating gene expression and cellular mechanics in these heart cells, as well as how emerin's localization, controlled by its secretory...